178 related articles for article (PubMed ID: 10330963)
1. Ten-year cost effectiveness of alternative immunosuppression regimens in cadaveric renal transplantation.
Schnitzler MA; Woodward RS; Lowell JA; Singer GG; Brennan DC
Transplant Proc; 1999 May; 31(3B Suppl):19S-21S. PubMed ID: 10330963
[No Abstract] [Full Text] [Related]
2. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
[TBL] [Abstract][Full Text] [Related]
3. Anti-interleukin 2-receptor antibodies: a comparative study with polyclonal antibodies in kidney transplantation: preliminary results.
Martins L; Henriques AC; Dias L; Sarmento AM; Pereira MC; Guimarães S
Transplant Proc; 2000 Dec; 32(8):2623-5. PubMed ID: 11134730
[No Abstract] [Full Text] [Related]
4. Polyclonal versus monoclonal induction therapy in a calcineurin inhibitor-free immunosuppressive therapy in renal transplantation: a comparison of efficacy and costs.
Sánchez-Escuredo A; Alsina A; Diekmann F; Revuelta I; Esforzado N; Ricart MJ; Cofan F; Fernandez E; Campistol JM; Oppenheimer F
Transplant Proc; 2015; 47(1):45-9. PubMed ID: 25645767
[TBL] [Abstract][Full Text] [Related]
5. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF
Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788
[TBL] [Abstract][Full Text] [Related]
6. The role of newer monoclonal antibodies in renal transplantation.
Vincenti F
Transplant Proc; 2001; 33(1-2):1000-1. PubMed ID: 11267163
[No Abstract] [Full Text] [Related]
7. Interleukin-2R antagonists in the prevention of acute rejection in living donor transplantation.
Ivanovski N; Popov Z; Kolevski P; Cakalaroski K; Spasovski G; Sikole A; Paneva-Masin J
Transplant Proc; 2001; 33(7-8):3203-4. PubMed ID: 11750374
[No Abstract] [Full Text] [Related]
8. Limited-dose Daclizumab versus Basiliximab: a comparison of cost and efficacy in preventing acute rejection.
Pham K; Kraft K; Thielke J; Oberholzer J; Sankary H; Testa G; Benedetti E
Transplant Proc; 2005 Mar; 37(2):899-902. PubMed ID: 15848569
[TBL] [Abstract][Full Text] [Related]
9. Rejection rate in living donor kidney transplantation with and without basiliximab in tacrolimus/mycophenolate mofetil-based protocol.
Rahamimov R; Yussim A; After T; Lustig S; Bar-Nathan N; Shaharabani E; Shapira Z; Shabthai E; Mor E
Transplant Proc; 2003 Mar; 35(2):653-4. PubMed ID: 12644082
[No Abstract] [Full Text] [Related]
10. Limited benefits of induction with monoclonal antibody to interleukin-2 receptor in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneous kidney-pancreas transplantation.
Lo A; Stratta RJ; Alloway RR; Egidi MF; Shokouh-Amiri MH; Grewal HP; Gaber AO
Transplant Proc; 2001; 33(1-2):1701-3. PubMed ID: 11267477
[No Abstract] [Full Text] [Related]
11. Renal transplantation in adolescents.
Smith JM; McDonald RA
Adolesc Med Clin; 2005 Feb; 16(1):201-14. PubMed ID: 15844392
[TBL] [Abstract][Full Text] [Related]
12. Comparison of basiliximab and daclizumab with triple immunosuppression in renal transplantation.
Aktas S; Colak T; Baskin E; Sevmis S; Ozdemir H; Moray G; Karakayali H; Haberal M
Transplant Proc; 2011 Mar; 43(2):453-7. PubMed ID: 21440732
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of three different immunosuppressive regimens to prevent chronic renal allograft rejection.
Burke GW; Ciancio C; Blomberg BB; Rosen A; Suzart K; Roth D; Kupin W; Esquenazi V; Miller J
Transplant Proc; 2002 Aug; 34(5):1610-1. PubMed ID: 12176505
[No Abstract] [Full Text] [Related]
14. Immunosuppressive therapy for kidney transplantation in children and adolescents: systematic review and economic evaluation.
Haasova M; Snowsill T; Jones-Hughes T; Crathorne L; Cooper C; Varley-Campbell J; Mujica-Mota R; Coelho H; Huxley N; Lowe J; Dudley J; Marks S; Hyde C; Bond M; Anderson R
Health Technol Assess; 2016 Aug; 20(61):1-324. PubMed ID: 27557331
[TBL] [Abstract][Full Text] [Related]
15. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal graft recipients.
Grego K; Arnol M; Bren AF; Kmetec A; Tomaziĉ J; Kandus A
Transplant Proc; 2007 Dec; 39(10):3093-7. PubMed ID: 18089329
[TBL] [Abstract][Full Text] [Related]
16. Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients.
Nair MP; Nampoory MR; Johny KV; Costandi JN; Abdulhalim M; El-Reshaid W; Al-Muzairai I; Ninan VT; Samhan M; Al-Mousawi M
Transplant Proc; 2001 Aug; 33(5):2767-9. PubMed ID: 11498153
[No Abstract] [Full Text] [Related]
17. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model.
Jones-Hughes T; Snowsill T; Haasova M; Coelho H; Crathorne L; Cooper C; Mujica-Mota R; Peters J; Varley-Campbell J; Huxley N; Moore J; Allwood M; Lowe J; Hyde C; Hoyle M; Bond M; Anderson R
Health Technol Assess; 2016 Aug; 20(62):1-594. PubMed ID: 27578428
[TBL] [Abstract][Full Text] [Related]
18. Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: a clinical study.
Lin M; Ming A; Zhao M
Clin Transplant; 2006; 20(3):325-9. PubMed ID: 16824149
[TBL] [Abstract][Full Text] [Related]
19. Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab.
Pascual J; Marcén R; Ortuño J
Nephrol Dial Transplant; 2001 Sep; 16(9):1756-60. PubMed ID: 11522853
[No Abstract] [Full Text] [Related]
20. Transplantation: Personalizing induction therapy in kidney transplantation.
Aull MJ; Suthanthiran M
Nat Rev Nephrol; 2009 Nov; 5(11):619-20. PubMed ID: 19855425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
